Drug Trial Radar · NCT04544293
Clinical Trial of Inhaled Molgramostim Nebulizer Solution in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
164
Actual
Start
May 19, 2021
Primary completion
Nov 30, 2023
Study completion May 30, 2027
Sponsor
- Lead sponsor
- Savara Inc.Industry
- Sponsor type
- Industry
- First posted
- Sep 10, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
160 subjects with autoimmune pulmonary alveolar proteinosis (aPAP) will be randomized to receive once daily treatment with inhaled molgramostim (MOL) or placebo (PBO) for 48 weeks. Subjects completing the 48-week placebo-controlled period will receive open-label treatment with once daily inhaled molgramostim for 96 weeks.
Conditions
- Autoimmune Pulmonary Alveolar Proteinosis
Interventions
MolgramostimDrug
Molgramostim 300 µg nebulizer solution
PlaceboDrug
Matching placebo nebulizer solution
Molgramostim Open-labelDrug
Molgramostim 300 µg nebulizer solution
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Percent (%) Predicted Diffusing Capacity of the Lung for Carbon Monoxide (DLCO) Adjusted for Hemoglobin Concentration to Week 24Time frame: From Baseline to Week 24
Locations
54 sites in 18 countries. Site status is shown where the registry gives one.
University Of Arkansas For Medical Services
Little Rock, Arkansas
UCLA David Geffen School of Medicine
Los Angeles, California
National Jewish Health
Denver, Colorado
Yale University
New Haven, Connecticut
University of Florida Health
Gainesville, Florida
Emory University
Atlanta, Georgia
Loyola University
Maywood, Illinois
University of Maryland Medical Center
Baltimore, Maryland
Washington University in St. Louis
St Louis, Missouri
Duke University Medical Center
Durham, North Carolina
Wake Med Health & Hospital
Raleigh, North Carolina
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio
Cleveland Clinic
Cleveland, Ohio
University of Pennsylvania Perelman School of Medicine - Pulmonology
Philadelphia, Pennsylvania
University of Pittsburgh
Pittsburgh, Pennsylvania
UT Southwestern Medical Center
Dallas, Texas
Royal Prince Alfred Hospital
Camperdown, New South Wales, Australia
Westmead Hospital
Westmead, New South Wales, Australia
Hôpital Erasme
Brussels, Brussels Capital, Belgium
UZ Leuven - Campus Gasthuisberg - Pneumologie
Leuven, Vlaams Brabant, Belgium
University of Calgary
Calgary, Alberta, Canada
St Joseph's Healthcare Hamilton Research
Hamilton, Ontario, Canada
University Institute of Cardiology and Respirology of Quebec
Québec, Quebec, Canada
Hôpital Louis Pradel
Bron, Auvergne-Rhône-Alpes, France
CHU Pontchaillou
Rennes, Brittany Region, France
Thoraxklinik Heidelberg gGmbH am Universitätsklinikum Heidelberg
Heidelberg, Baden-Wurttemberg, Germany
Asklepios Fachkliniken Muenchen-Gauting
Muenchen-Gauting, Bavaria, Germany
Ruhrlandklinik Westdeutsches Lungenzentrum
Essen, North Rhine-Westphalia, Germany
Attikon University Hospital
Athens, Greece
St. Vincent's University Hospital
Dublin, Ireland
Fondazione IRCCS Policlinico San Matteo
Pavia, Lombardy, Italy
Aichi Medical University Hospital
Nagakute, Japan
Chiba University Hospital - Respiratory Medicine
Chiba, Chiba, Japan
Hokkaido University Hospital
Sapporo, Hokkaidô, Japan
Kanagawa Cardiovascular and Respiratory Center
Yokohama, Kanagawa, Japan
Kumamoto University Hospital
Kumamoto, Kumamoto, Japan
Tohoku University Hospital - Respiratory Tract Medicine
Sendai, Miyagi, Japan
National Hospital Organization Kinki-Chuo Chest medical Center
Sakai, Osaka, Japan
Saitama Red Cross Hospital
Saitama, Saitama, Japan
Kyorin University Hospital
Mitaka, Tokyo, Japan
Showing 40 of 54 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.